For many patients, a diagnosis of neovascular glaucoma begins as a frightening struggle with vision loss. It’s a severe form of the disease where new, abnormal blood vessels grow across the iris and the angle of the eye, blocking the drainage of fluid and causing pressure to spike. For years, clinicians have treated this primarily as an ophthalmic emergency—a crisis of the eye that requires urgent intervention to save what sight remains.
However, a growing body of evidence suggests that these abnormal vessels may be more than just a local complication. They may be a visible manifestation of a much larger, systemic failure. New research indicates that neovascular glaucoma (NVG) could serve as a critical red flag for severe cardiovascular dysfunction, signaling that the patient is at a significantly higher risk for heart attack, stroke, and premature death.
The connection stems from a fundamental biological process: ischemia. When tissues are starved of oxygen due to poor blood flow, the body releases growth factors to sprout new blood vessels in a desperate attempt to restore circulation. While this happens in the eye in NVG patients—often triggered by diabetic retinopathy or retinal vein occlusions—the same vascular fragility and dysfunction are likely occurring throughout the rest of the body’s arterial system.
This shift in perspective transforms the role of the eye care provider. Rather than focusing solely on intraocular pressure, the discovery suggests that the ophthalmologist or optometrist may be the first clinician to identify a patient in the midst of a systemic vascular collapse.
The Data: A Window Into Systemic Risk
The link between NVG and systemic health was not discovered in a vacuum, but rather began as a clinical observation. Dr. Jaime Levy, an ophthalmologist at Hadassah University Medical Center in Israel, noted a pattern in his practice: patients with neovascular glaucoma often seemed “systemically more ill” than those with similar retinal diseases who had not developed glaucoma. They presented with more frequent hospitalizations and a heavier burden of comorbid cardiovascular diseases.
To test this hypothesis, Levy and his colleagues conducted a retrospective analysis using the TriNetX database, a massive network of electronic health records. The researchers employed propensity score matching to ensure a fair comparison, creating two groups of 17,020 patients each. One group suffered from neovascular glaucoma, while the control group consisted of patients with cataracts—a common ophthalmic condition that does not typically signal systemic vascular failure.
The results were stark. Patients with NVG didn’t just have worse eye health; they had significantly higher rates of life-threatening cardiovascular events across every metric measured.
| Clinical Outcome | NVG Patient Group | Cataract Control Group |
|---|---|---|
| Acute Myocardial Infarction | 8.1% | 4.83% |
| Stroke | 7.51% | 4.25% |
| Cardiac Arrest | 3.02% | 1.73% |
| All-Cause Mortality | 18.37% | 9.76% |
| Major Adverse Cardiovascular Events (MACE) | 26.59% | 15.68% |
Beyond the Underlying Eye Disease
One of the most critical findings of the study, published in Scientific Reports, is that the increased risk persists even when accounting for the diseases that typically cause NVG. Many patients develop this form of glaucoma because they already have proliferative diabetic retinopathy or retinal vein occlusions—both of which are known to be associated with vascular issues.
However, Levy found that among patients who had the same underlying retinal disease, those who progressed to neovascular glaucoma still faced higher mortality and cardiovascular risks than those who did not. This suggests that NVG is not merely a symptom of diabetes or a vein blockage, but a marker of “particularly severe systemic vascular dysfunction.”
the development of these abnormal vessels in the eye acts as a biological proxy. If the body’s compensatory mechanisms are failing so significantly that new vessels are sprouting in the eye to combat ischemia, it is highly probable that the heart and brain are under similar, if not more severe, stress.
The Path Toward Multidisciplinary Care
The implications for patient care are immediate. Because optometrists and ophthalmologists are often the first to diagnose NVG, they are uniquely positioned to trigger a systemic health screening that might otherwise be delayed.
This does not mean that eye specialists are expected to manage heart disease or prescribe anticoagulants. Instead, it underscores the necessity of a multidisciplinary approach. When a diagnosis of neovascular glaucoma is made, the clinical workflow should ideally expand to include:
- Immediate Primary Care Coordination: Alerting the patient’s internist or primary care physician to the diagnosis as a marker of vascular risk.
- Cardiovascular Screening: Prioritizing evaluations for hypertension, carotid artery stenosis, or coronary artery disease.
- Integrated Monitoring: Ensuring that the management of the patient’s systemic health (such as aggressive blood pressure and glucose control) is aligned with the treatment of their ocular pressure.
By treating the eye as a diagnostic window, clinicians can move from a reactive model—treating a stroke after it happens—to a proactive model, using ocular findings to identify high-risk patients before a major cardiovascular event occurs.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult with a licensed healthcare provider for diagnosis and treatment of any medical condition.
As researchers continue to analyze the TriNetX data and other large-scale cohorts, the next step will be determining if aggressive systemic vascular intervention can slow the progression of neovascular glaucoma itself. Further clinical guidelines are expected to emerge as the medical community integrates these findings into standard ophthalmic practice.
Do you believe integrated care between specialists is currently sufficient in your healthcare experience? Share your thoughts in the comments or share this article with a colleague.
